Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Exploring isoxazoles and pyrrolidinones decorated with the 4,6-dimethoxy-1,3,5-triazine unit as human farnesyltransferase inhibitors.

Lucescu L, Ghinet A, Shova S, Magnez R, Thuru X, Farce A, Rigo B, Belei D, Dubois J, Bîcu E.

Arch Pharm (Weinheim). 2019 May;352(5):e1800227. doi: 10.1002/ardp.201800227. Epub 2019 Apr 4.

PMID:
30947375
2.

Toward the Discovery of a Novel Class of YAP⁻TEAD Interaction Inhibitors by Virtual Screening Approach Targeting YAP⁻TEAD Protein⁻Protein Interface.

Gibault F, Coevoet M, Sturbaut M, Farce A, Renault N, Allemand F, Guichou JF, Drucbert AS, Foulon C, Magnez R, Thuru X, Corvaisier M, Huet G, Chavatte P, Melnyk P, Bailly F, Cotelle P.

Cancers (Basel). 2018 May 8;10(5). pii: E140. doi: 10.3390/cancers10050140.

3.

PD-1/PD-L1 binding studies using microscale thermophoresis.

Magnez R, Thiroux B, Taront S, Segaoula Z, Quesnel B, Thuru X.

Sci Rep. 2017 Dec 15;7(1):17623. doi: 10.1038/s41598-017-17963-1.

4.

Slowing down fat digestion and absorption by an oxadiazolone inhibitor targeting selectively gastric lipolysis.

Point V, Bénarouche A, Zarrillo J, Guy A, Magnez R, Fonseca L, Raux B, Leclaire J, Buono G, Fotiadu F, Durand T, Carrière F, Vaysse C, Couëdelo L, Cavalier JF.

Eur J Med Chem. 2016 Nov 10;123:834-848. doi: 10.1016/j.ejmech.2016.08.009. Epub 2016 Aug 8.

PMID:
27543878

Supplemental Content

Loading ...
Support Center